Nilandrone

• Androgen Antagonists
• Antineoplastic Agents
• ATC:L02BB02

• Anandron
• Nilandron
• Nilandrone
• Nilutamida [Spanish]
• Nilutamide [Usan:Ban:Inn]
• Nilutamidum [Latin]

No information avaliable

C₁₂H₁₀F₃N₃O₄

http://www.rxlist.com/cgi/generic2/nilutam.htm

No hay información disponible

317.221 g/mol

No information avaliable

No hay información disponible

Solid

2.232

Tableta

Para su uso en combinación con la castración quirúrgica para el tratamiento de cáncer de próstata metastásico (estadio D2)

Nilutamida es un agente antineoplásico hormonal utilizado principalmente en el tratamiento del cáncer de próstata. Nilutamida es un puro, medicamentos anti-andrógenos con afinidad por los receptores de andrógenos (pero no de progestágeno, estrógenos, o los receptores de glucocorticoides). En consecuencia, los bloques de nilutamida la acción de los andrógenos de origen suprarrenal y los testículos, que estimulan el crecimiento del tejido prostático normal y maligno. Próstata el cáncer es en su mayoría dependientes de los andrógenos y puede ser tratada con la castración quirúrgica o química. Hasta la fecha, la monoterapia con antiandrógenos no ha sido demostrado que es equivalente a la castración.

Absorbe rápida y completamente, produciendo concentraciones plasmáticas elevadas y persistentes.

Los síntomas de sobredosis incluyen mareo, malestar general, dolor de cabeza, náuseas y vómitos.

Patients should be informed that NILANDRON tablets should be started on the day of, or on the day after, surgical castration. They should also be informed that they should not interrupt their dosing of NILANDRON or stop taking this medication without consulting their physician.
Because of the possibility of interstitial pneumonitis, patients should also be told to report immediately any dyspnea or aggravation of pre-existing dyspnea.

Because of the possibility of hepatitis, patients should be told to consult with their physician should nausea, vomiting, abdominal pain, or jaundice occur.
Because of the possibility of an intolerance to alcohol (facial flushes, malaise, hypotension) following ingestion of NILANDRON, it is recommended that intake of alcoholic beverages be avoided by patients who experience this reaction. This effect has been reported in about 5% of patients treated with NILANDRON.

In clinical trials, 13% to 57% of patients receiving NILANDRON reported a delay in adaptation to dark, ranging from seconds to a few minutes, when passing from a lighted area to a dark area. This effect sometimes does not abate as drug treatment is continued. Patients who experience this effect should be cautioned about driving at night or through tunnels. This effect can be alleviated by the wearing of tinted glasses.

Humanos y otros mamíferos